Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Doo-Ho | - |
dc.contributor.author | Jang, Jin-Young | - |
dc.contributor.author | Kang, Jae Seung | - |
dc.contributor.author | Kim, Jae Ri | - |
dc.contributor.author | Han, Youngmin | - |
dc.contributor.author | Kim, Eunjung | - |
dc.contributor.author | Kwon, Wooil | - |
dc.contributor.author | Kim, Sun-Whe | - |
dc.date.available | 2021-03-16T05:40:11Z | - |
dc.date.created | 2021-03-16 | - |
dc.date.issued | 2018-11 | - |
dc.identifier.issn | 2508-5778 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80442 | - |
dc.description.abstract | Backgrounds/Aims We performed a retrospective, single-center cohort study to evaluate the impact of various treatment modalities and recent changes in treatment modalities, including the increased application of chemotherapy, on survival in patients with pancreatic cancer. Methods All patients with pancreatic cancer who were diagnosed and treated at Seoul National University Hospital between January 2007 and December 2014 were registered in a prospective clinical database and included in this retrospective study. All patients' radiologic imaging diagnoses were re-reviewed according to the National Cancer Center Network guidelines. The patients were divided into four groups according to their clinical stage, and each clinical stage group was further divided into four groups according to treatment modality. Results Overall, 475 (28.9%) patients had resectable pancreatic cancer, 129 (7.8%) patients borderline resectable pancreatic cancer, 384 (23.3%) patients locally advanced pancreatic cancer, and 658 (40.0%) patients metastatic pancreatic cancer. Among the patients with borderline resectable pancreatic cancer, the median survival was significantly longer in the neoadjuvant therapy (NAT)+surgery groups (24 months) than the surgery without NAT (16 months) group (p=0.049). A multivariate survival analysis revealed that compared with the surgery group, the 5-year mortality risk was decreased by 35% in the NAT+surgery group (24 vs. 20 months, p=0.045). Conclusions This retrospective cohort study showed that the rates of resectable and surgically treatable pancreatic cancer were 29.1% and 32.2%, which are higher than those reported previously, and aggressive NAT for select advanced-stage patients could lead to better survival outcomes. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | The Korean Association of Hepato-Biliary-Pancreatic Surgery | - |
dc.relation.isPartOf | Ann Hepatobiliary Pancreat Surg. | - |
dc.title | Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.doi | 10.14701/ahbps.2018.22.4.386 | - |
dc.identifier.bibliographicCitation | Ann Hepatobiliary Pancreat Surg. , v.22, no.4, pp.386 - 396 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 396 | - |
dc.citation.startPage | 386 | - |
dc.citation.title | Ann Hepatobiliary Pancreat Surg. | - |
dc.citation.volume | 22 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Lee, Doo-Ho | - |
dc.subject.keywordAuthor | Neoadjuvant therapy | - |
dc.subject.keywordAuthor | Survival rate | - |
dc.subject.keywordAuthor | Pancreas neoplasms | - |
dc.description.journalRegisteredClass | other | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.